AbbVie Partners with Gilgamesh Pharmaceuticals to Develop Next-Generation Therapies for Psychiatric Disorders
Shots:
- AbbVie & Gilgamesh have teamed up & signed an option-to-license agreement to develop neuroplastogens through AbbVie's psychiatry knowledge & Gilgamesh's research platform
- As per the agreement, both companies will research & develop a portfolio of neuroplastogens. AbbVie, upon option exercise, will handle development & commercialization while Gilgamesh will obtain $65M upfront and a total of up to $1.95B as option exercise fee & milestones plus mid-single to low-double net-sales based tiered royalties
- Neuroplastogens are the next-generation therapies designed for treating various psychiatric conditions, incl. mood & anxiety disorders while addressing the challenges seen with first-generation compounds
Ref: Medincell | Image: Medincell
Related News:- AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
